Stockreport

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly [Read more]